Contents14 sections
Aromasin (exemestane) and Arimidex (anastrozole) are the two aromatase inhibitors (AIs) men most often compare. Both are breast cancer drugs that lower estrogen by blocking aromatase, the enzyme that turns testosterone into estradiol. Men use them off-label on testosterone replacement therapy (TRT) and on steroid cycles to stop estradiol climbing too high. The two drugs get there by different routes: anastrozole blocks the enzyme reversibly, while exemestane permanently disables it.
The old idea that either drug is a post-cycle therapy (PCT) treatment is wrong, and so are popular claims about which one is “stronger.” This guide covers how they work, what the research in men shows, and how they compare on TRT and on cycles. Neither drug is approved for men, and nothing here is a recommendation to take one.
Key Takeaways
- Arimidex (anastrozole) is a non-steroidal, reversible aromatase inhibitor. Aromasin (exemestane) is a steroidal, irreversible one that permanently disables the enzyme.
- In the largest head-to-head trial, more than 7,500 women with breast cancer, the two drugs worked equally well. Neither is clearly “stronger” in practice.
- Men need some estradiol. In a 2013 study in healthy men, blocking it raised body fat and lowered sexual desire, even at the same testosterone dose.
- Neither drug is a PCT drug. Recovery after a cycle is usually attempted with SERMs such as tamoxifen or clomiphene, which leave estrogen in place.
- Most men on a well-dosed TRT protocol do not need an AI. A high estradiol number without symptoms is not, on its own, a reason to start one.
Aromasin vs Arimidex at a Glance
The two drugs reach the same goal, lower estradiol, by different routes. Here is how they compare on the points that matter to men.
| Arimidex | Aromasin | |
|---|---|---|
| Generic name | Anastrozole | Exemestane |
| Type | Non-steroidal (triazole) | Steroidal (related to androstenedione) |
| How it blocks aromatase | Reversibly: competes for the enzyme | Irreversibly: permanently inactivates it |
| Approved use | Breast cancer in postmenopausal women | Breast cancer in postmenopausal women |
| First US approval | 1995 | 1999 |
| Standard clinical dose | 1mg once a day | 25mg once a day after a meal |
| Half-life | About 50 hours | About 24 hours |
| Androgenic metabolite | No | Yes (17-hydroexemestane) |
| Approved for men | No | No |
| Prohibited by WADA | Yes, at all times | Yes, at all times |
What Is Arimidex (Anastrozole)?
Arimidex is the brand name for anastrozole. It was developed by Zeneca (now AstraZeneca) in the early 1990s and approved in the US in 1995 to treat breast cancer in postmenopausal women. Many breast cancers grow in response to estrogen. After menopause, most of a woman’s estrogen is made by aromatase in fat and other tissues, so blocking that enzyme takes away the tumor’s fuel.
Anastrozole is a non-steroidal inhibitor. It binds to aromatase and blocks it, but the binding is reversible: when the drug level falls, the enzyme starts working again. Its half-life is about 50 hours, so levels build up over the first week or two of regular dosing. In postmenopausal women, the drug’s label reports that 1mg a day cuts estradiol by about 70% within 24 hours and by about 80% after two weeks.
Anastrozole in Men
In men, estradiol tells the brain there is enough testosterone. Lowering it removes that brake, so the pituitary releases more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the testes make more testosterone. This effect of aromatase inhibitors in men is the reason anastrozole is used off-label in some men with low testosterone or infertility.
Two trials in older men show both sides of the trade. In a 12-week study, anastrozole at 1mg daily or 1mg twice a week raised testosterone in men with low or borderline-low levels, while estradiol fell only modestly. But in a year-long placebo-controlled trial in older men with low testosterone, 1mg daily raised testosterone yet spine bone density fell compared with placebo. Higher testosterone did not make up for less estrogen in bone.
In infertile men with a low testosterone-to-estradiol ratio, anastrozole has been shown to improve that ratio and semen quality. That is a specialist use under a urologist, not a bodybuilding one. Our guide to anastrozole for men covers the male data in more depth.
Peptides
Overview
- Form: Oral Capsule
- Dosage: 0.5mg 1-2 times weekly
- Typical Cycle: As needed based on blood work (best for managing sides on cycle)
- Cost: $64.03
- Stacking Options: Testosterone enanthate or cypionate
Pros
- Well-established efficacy — ATAC trial showed superior disease-free survival versus tamoxifen in postmenopausal hormone-receptor-positive breast cancer
- Substantially lower risk of endometrial cancer and thromboembolic events than tamoxifen
- Once-daily oral dosing, few significant drug interactions
Cons
- Accelerated bone mineral density loss, with elevated fracture risk over years of use
- Arthralgia and joint stiffness are common and a frequent reason patients stop treatment
- Ineffective in premenopausal women unless ovarian function is suppressed, since it only blocks peripheral aromatisation
What Is Aromasin (Exemestane)?
Aromasin is the brand name for exemestane. It was developed in Italy by Farmitalia Carlo Erba, approved in the US in 1999 for advanced breast cancer in postmenopausal women, and is now sold by Pfizer. Like anastrozole, it lowers estrogen by targeting aromatase. Unlike anastrozole, it is a steroid.
Exemestane is built on the same steroid frame as androstenedione, one of aromatase’s natural targets. The enzyme mistakes it for its normal substrate, binds it and is permanently inactivated. This is why exemestane is called a “suicide” inhibitor or aromatase inactivator. Estrogen production only recovers as the body makes new enzyme.
Exemestane’s half-life is about 24 hours, and the label advises taking it after a meal, since food improves absorption. The body converts part of each dose into 17-hydroexemestane, a metabolite that binds the androgen receptor. That weak androgenic activity is often cited as an advantage for men, but its practical effect at the doses men report has not been studied.
Exemestane in Men
Human data in men are thin. A small dose-finding study in healthy young men found that exemestane lowered estradiol and raised testosterone within days. Beyond that, most of what is written about exemestane for men comes from user reports, not trials. Our article on exemestane side effects covers the clinical safety data.
How Aromasin and Arimidex Really Differ
Reversible vs Irreversible
This is the main difference. Anastrozole works only while the drug is in the blood; stop it and the enzyme comes back as the drug clears, which with a 50-hour half-life takes several days. Exemestane’s effect outlasts the drug, because each disabled enzyme stays disabled until the body replaces it. With either drug, a change in dose takes time to show up in blood work.
The 80% vs 85% Myth
Older bodybuilding articles claim Aromasin is stronger because it cuts estrogen by 85% versus 80% for Arimidex. The 80% figure is from Arimidex’s label, in postmenopausal women; the two numbers come from different studies, measured in different ways, and cannot be compared. When researchers measure whole-body aromatase activity directly, both drugs at their standard doses block well over 90% of it in postmenopausal women. In men on testosterone, the size of the estradiol drop depends far more on the dose and the individual than on which drug is used.
The IGF-1 Claim
Another popular claim is that exemestane raises IGF-1 and builds muscle in a way no other AI can. There is no good evidence for this in men. No trial has shown that exemestane adds muscle, and in men part of testosterone’s effect on growth hormone appears to run through estrogen, so cutting estrogen is not an obvious route to more IGF-1. Treat this one as forum lore.
Head-to-Head Results
The only large direct comparison is the MA.27 trial, which randomly assigned more than 7,500 postmenopausal women with early breast cancer to five years of exemestane or anastrozole. Cancer outcomes were the same. Side effects differed only at the margins: osteoporosis and raised cholesterol and triglycerides were less frequent with exemestane, while mild liver test changes and rare episodes of atrial fibrillation were less frequent with anastrozole. These were women with cancer taking clinical doses, so the findings only hint at what happens in men.
Why Men Need Some Estrogen
In men, most estradiol is made from testosterone by aromatase in fat, muscle, bone and the brain. More testosterone usually means more estradiol, which is why levels climb on TRT and on steroid cycles. That estradiol is not just a side effect to be removed. It does real work:
- Bone: Estradiol is a main regulator of bone turnover in men. Too little speeds bone loss.
- Sexual function: Libido and erectile function depend on estradiol as well as testosterone.
- Body fat: Low estradiol tends to raise body fat, even when testosterone is normal.
- Mood and joints: Men whose estradiol has been driven too low commonly report low mood, fatigue and aching joints.
The clearest evidence comes from a 2013 study in the New England Journal of Medicine in healthy men aged 20 to 50. Researchers shut down the men’s own hormone production and replaced testosterone at set doses, with or without anastrozole to block estradiol. Lean mass and strength tracked testosterone. Body fat rose mainly when estradiol was blocked, and sexual desire and erectile function depended on estradiol as well as testosterone.
Aromasin vs Arimidex on TRT
On TRT, estradiol rises along with testosterone. For many men that is normal and harmless. Guidelines treat aromatase inhibitors in men as off-label drugs with limited long-term safety data, and they do not support adding one routinely to TRT.
Clinicians who manage estradiol on TRT usually start with the testosterone itself: a lower dose, or smaller and more frequent injections that avoid big peaks. Body fat matters too, since fat tissue is a major site of aromatase. Our guide on the best way to control estradiol on TRT covers these options.
When an AI Is Used on TRT
When a doctor does add an AI, it is usually for clear symptoms, such as tender or growing breast tissue, together with a high estradiol result. Standard estradiol immunoassays are less accurate at male levels, so a sensitive test (LC-MS/MS) is preferred. Commonly reported TRT doses are far below breast cancer doses:
| Drug | Commonly Reported TRT Use | Notes |
|---|---|---|
| Anastrozole | 0.25-0.5mg once or twice a week | Long half-life, so it builds up with frequent dosing |
| Exemestane | 6.25-12.5mg two or three times a week | Irreversible; taken with food |
These figures come from clinic and user reports, not from trials of men on TRT. Small changes in dose can move estradiol a lot, which is why follow-up blood work matters.
The Risk of Crashing Estradiol
The most common problem with AIs on TRT is not too much estrogen but too little. Symptoms men report when estradiol has been driven too low include:
- Joint pain or stiffness
- Low libido and erectile problems
- Low mood, anxiety or fatigue
- Dry skin and poor sleep
Over months, low estradiol also costs bone, as the year-long anastrozole trial in older men showed. That is the main argument against taking an AI “just in case.” Several of these symptoms overlap with those of high estradiol, and only blood work tells them apart.
Aromasin vs Arimidex on a Steroid Cycle
On cycles the logic is the same, but the numbers are bigger. Supraphysiological doses of testosterone push estradiol well above the normal male range, and some users take an AI to limit water retention, raised blood pressure and breast tissue growth (gynecomastia).
Whether an AI is even relevant depends on the compounds in the cycle:
- Aromatize strongly: Testosterone esters and Dianabol (methandrostenolone). These are the cycles where estrogen control comes up most.
- Aromatize weakly: Nandrolone (Deca) converts to estrogen at a much lower rate than testosterone, but it also has progesterone-like activity that an AI does not touch.
- Do not aromatize: Trenbolone and DHT derivatives such as Masteron, Primobolan, Anavar and Winstrol. See our list of steroids that don’t cause gyno.
- Anadrol (oxymetholone): Does not aromatize, yet users commonly report estrogen-like side effects. The cause is not well established, and an AI cannot block a conversion that is not happening.
Commonly Reported On-Cycle Use
Users commonly report the following on testosterone-based cycles. These are not clinical doses and they are not recommendations. No trial has tested aromatase inhibitors in men running steroid cycles.
| Drug | Commonly Reported On-Cycle Dose | Notes |
|---|---|---|
| Anastrozole | 0.25-1mg every other day | Usually adjusted to blood work; clears slowly |
| Exemestane | 12.5-25mg every other day or daily | Taken with food; effect outlasts the drug |
Users who run an AI without blood work often overshoot, and crashed estradiol on a cycle brings the same joint pain, low libido and low mood as on TRT.
Gyno: Why a SERM Usually Comes First
If breast tissue is already growing, the evidence favors a selective estrogen receptor modulator (SERM) such as tamoxifen over an AI. In men taking the anti-androgen bicalutamide for prostate cancer, a randomized trial found that tamoxifen prevented gynecomastia far more often than anastrozole did. In a randomized trial in teenage boys with pubertal gynecomastia, anastrozole worked no better than placebo. A SERM blocks estrogen at the breast tissue itself, while an AI only lowers how much estrogen is made.
SERMs & AIs
Overview
- Form: Oral Capsules
- Dosage: 25-40 mg daily for PCT or for gyno flare-ups
- Typical Cycle: 4-6 weeks
- Cost: $81.95
- Stacking Options: Higher testosterone doses or post-cycle recovery
Pros
- Large mortality benefit in ER-positive breast cancer; five years of adjuvant treatment cuts recurrence roughly by half and breast cancer mortality by about a third, with the effect persisting well past the treatment period
- Works in premenopausal and postmenopausal women alike, unlike aromatase inhibitors, which makes it the default for younger patients
- Bone-protective in postmenopausal women, since it acts as a partial estrogen agonist in bone — the reverse of anastrozole's main liability
Cons
- Endometrial hyperplasia and a two-to-three-fold increase in endometrial cancer risk in postmenopausal women, requiring investigation of any abnormal bleeding
- Elevated risk of venous thromboembolism and pulmonary embolism, particularly around surgery or immobility
- Hot flashes, vasomotor symptoms and mood effects are common; CYP2D6 status and strong inhibitors such as certain SSRIs can reduce conversion to the active metabolite
Are Aromasin or Arimidex Good for PCT?
No. This is where many older guides went wrong. Post-cycle therapy (PCT) is meant to restart the body’s own testosterone production after a cycle has shut it down. Aromatase inhibitors are not the standard tools for this.
By the end of a cycle, the problem is usually too little natural testosterone, not too much estrogen. Estradiol tends to fall along with testosterone as the drugs clear. Adding an AI at that point can push it lower still, stacking joint pain, low libido and low mood on top of the symptoms of low testosterone.
The drugs most commonly used for PCT are SERMs: tamoxifen (Nolvadex) and clomiphene (Clomid). They block estrogen’s feedback signal in the brain, which raises LH and FSH, while leaving estradiol available for bone, libido and mood. AIs also raise LH by lowering estradiol, which is why some users add a small dose, but this is not a standard protocol and no trial has shown that it improves recovery.
Recovery is also less certain than most PCT guides suggest. In a 2023 study of 641 men seen at a UK clinic after stopping anabolic steroids, only 48% had fully recovered their reproductive hormones. Our guide to PCT for testosterone covers what the research shows.
Side Effects Compared
Both drugs share the side effects of low estrogen, and in men these mostly come from overshooting. Several rows below come from the MA.27 trial in women, because comparable data in men do not exist.
| Side Effect | Arimidex | Aromasin |
|---|---|---|
| Joint pain and stiffness | Common when estradiol falls too low | Common when estradiol falls too low |
| Bone loss | Shown in older men over one year | Expected with low estradiol; little data in men |
| Low libido, erectile problems | Yes, if estradiol falls too low | Yes, if estradiol falls too low |
| Raised cholesterol and triglycerides | More frequent than exemestane (MA.27, women) | Less frequent than anastrozole (MA.27, women) |
| Mild liver test changes | Less frequent than exemestane (MA.27, women) | More frequent than anastrozole (MA.27, women) |
| Androgenic effects | None expected | Possible from its androgenic metabolite; not well studied |
In men, the biggest risk with either drug is not a rare drug reaction. It is too little estradiol for too long.
Aromasin vs Arimidex: Which Is Better?
For most men the honest answer is neither, because most men on TRT do not need an AI and neither drug belongs in PCT. When estrogen control is truly needed, the evidence does not show that one beats the other. The practical differences are:
- Arimidex: Its effect fades as the drug clears, which makes it easier to adjust. It builds up with regular dosing, so small, spaced doses go a long way.
- Aromasin: It keeps working after the drug is gone. It has a mildly androgenic metabolite and, in women, a slightly kinder effect on cholesterol, but there are far fewer data in men.
- For gynecomastia: A SERM such as tamoxifen has better evidence than either AI.
- For PCT: SERMs are the commonly used drugs; AIs are not.
Whichever drug is used, blood work before and during use is the only way to know where estradiol actually is.
The Bottom Line
Aromasin and Arimidex lower estrogen equally well in the best head-to-head data. For most men the real question is whether they need an aromatase inhibitor at all, and usually they do not.
- Arimidex blocks aromatase reversibly; Aromasin destroys it. That changes how they are dosed, not which one works better.
- Men need estradiol for bone, libido and body composition, and crashing it with an AI causes real harm. On TRT, the testosterone dose and injection frequency come first.
- Neither drug is a PCT drug, and neither is the best tool for established gyno. SERMs such as tamoxifen have better evidence for both.
Frequently Asked Questions
Disclaimer
Please read carefully
The information on this site is for educational and informational purposes only, and is not medical advice. Always consult a qualified healthcare professional before using any supplement or medication, or making changes to your health, fitness, or nutrition routine.
Not medical advice
Content here is not a substitute for professional medical advice.
Consult your doctor
Talk to your doctor before starting any supplement or new routine.
Use at your own risk
We are not responsible for adverse effects from acting on this.
Do your research
Make informed decisions about your own health.
No guarantees
Individual results vary. No claims about outcomes.
Important — Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or your local emergency number right away.
